No abstract available
Publication types
-
Clinical Trial, Phase I
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adolescent
-
Adult
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzenesulfonates / administration & dosage
-
Bevacizumab
-
Child
-
Child, Preschool
-
Drug Synergism
-
Erlotinib Hydrochloride
-
Female
-
Humans
-
Indoles / administration & dosage
-
Male
-
Molecular Targeted Therapy* / methods
-
Neurofibromatosis 2 / drug therapy*
-
Neurofibromatosis 2 / genetics
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / administration & dosage
-
Pyrroles / administration & dosage
-
Quinazolines / administration & dosage
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives
-
Sorafenib
-
Sunitinib
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Treatment Outcome
-
Valproic Acid / administration & dosage
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Young Adult
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Benzenesulfonates
-
Indoles
-
Phenylurea Compounds
-
Pyridines
-
Pyrroles
-
Quinazolines
-
Vascular Endothelial Growth Factor A
-
Niacinamide
-
Bevacizumab
-
Valproic Acid
-
temsirolimus
-
Sorafenib
-
Erlotinib Hydrochloride
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sunitinib
-
Sirolimus